- Home
- PDM vs SPRY Comparison
PDM vs SPRY Comparison
Compare PDM & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDM
- SPRY
- Stock Information
- Founded
- PDM 1997
- SPRY 2015
- Country
- PDM United States
- SPRY United States
- Employees
- PDM N/A
- SPRY N/A
- Industry
- PDM Building operators
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- PDM Real Estate
- SPRY Health Care
- Exchange
- PDM Nasdaq
- SPRY Nasdaq
- Market Cap
- PDM 1.1B
- SPRY 1.1B
- IPO Year
- PDM N/A
- SPRY N/A
- Fundamental
- Price
- PDM $8.15
- SPRY $8.66
- Analyst Decision
- PDM Buy
- SPRY Strong Buy
- Analyst Count
- PDM 5
- SPRY 4
- Target Price
- PDM $9.40
- SPRY $31.25
- AVG Volume (30 Days)
- PDM 839.1K
- SPRY 1.7M
- Earning Date
- PDM 10-27-2025
- SPRY 11-10-2025
- Dividend Yield
- PDM 3.08%
- SPRY N/A
- EPS Growth
- PDM N/A
- SPRY N/A
- EPS
- PDM N/A
- SPRY N/A
- Revenue
- PDM $565,372,000.00
- SPRY $112,339,000.00
- Revenue This Year
- PDM N/A
- SPRY N/A
- Revenue Next Year
- PDM N/A
- SPRY $193.13
- P/E Ratio
- PDM N/A
- SPRY N/A
- Revenue Growth
- PDM N/A
- SPRY 22367.80
- 52 Week Low
- PDM $5.46
- SPRY $8.32
- 52 Week High
- PDM $10.72
- SPRY $18.90
- Technical
- Relative Strength Index (RSI)
- PDM 41.50
- SPRY 34.69
- Support Level
- PDM $7.85
- SPRY $8.32
- Resistance Level
- PDM $8.90
- SPRY $9.01
- Average True Range (ATR)
- PDM 0.23
- SPRY 0.52
- MACD
- PDM -0.03
- SPRY -0.09
- Stochastic Oscillator
- PDM 24.29
- SPRY 13.48
About PDM Piedmont Office Realty Trust Inc.
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across major U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.